Question 1

Has Patrick McGarrah, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $183,570 in general payments to Patrick McGarrah, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Patrick McGarrah, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Patrick McGarrah, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Amgen	1	$183,315
Boehringer Ingelheim Pharma GmbH & Co.kg	2	$143
AstraZeneca	2	$112

Drug	Claims	Cost to plans & patients
Everolimus	11	$24,017
Prochlorperazine Maleate	49	$527
Olanzapine	33	$469
Dexamethasone	52	$420
Ondansetron Hcl	46	$311
Levothyroxine Sodium	18	$171
Oxycodone Hcl	13	$171

Patrick McGarrah, MD

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other medical oncology in Rochester